Indication
PARP inhibitor
2 clinical trials
3 products
1 drug
Clinical trial
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas PatientsStatus: Recruiting, Estimated PCD: 2024-09-13
Product
OlaparibProduct
TemozolomideClinical trial
Phase II Clinical Trial Combining the Hedgehog Inhibitor Vismodegib With the PD-L1 Inhibitor Atezolizumab in Patients With Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal CancerStatus: Recruiting, Estimated PCD: 2028-04-01
Product
VismodegibDrug
Atezolizumab